Why Sex Differences in Medicine Matter: From NIH Policy to Ambien Dosing and Heart Attack Symptoms

Sex differences in medicine extend beyond biology to how research is designed, funded, and practiced. This episode examines the historical underrepresentation of women in trials, how sex differences influence drug dosing and symptom interpretation, and how policy and clinical practice are evolving toward more precise, socially aware medicine.

• Historical exclusion of women in NIH-funded trials and the 1993 policy change.
• Biology is not binary; pink and blue buckets overlook overlaps and diversity.
• Ambien dosing highlights sex-specific pharmacology and safety debates.
• Precision medicine must account for social determinants and real-world care gaps.

Introduction

The Short Wave episode examines how sex and gender influence medical science, care, and policy. Through conversations with philosophers, neuroscientists, and clinicians, the show traces the legacy of женщины being excluded from early drug trials, how that gap still echoes in today’s research, and what a more precise, inclusive approach could look like in medicine and drug development. The episode also foregrounds the complexity of defining sex in medical contexts, and the ongoing tension between biological explanations and social determinants of health.

Historical Context: Exclusion and Policy Shifts

A historical thread runs through the discussion: the thalidomide tragedy in the late 1950s and 1960s led to regulatory caution that effectively excluded many women of childbearing potential from early drug trials. The FDA formalized this in 1977, and in 1993 the NIH established a policy requiring researchers to include women and People of Color in federally funded medical trials. Marina DiMarco, a philosopher of science, explains that these shifts emerged from data gaps and activist pressure, gradually expanding the representation of women and other groups in biomedical research. Yet defining sex and gender remains contentious, and researchers increasingly recognize that representation alone does not guarantee equity or accurate conclusions, underscoring the need for nuanced study design.

Two-Bucket Thinking and Data Diversity

One focal point is the oversimplified blue/pink or male/female framework. Donna Maney, a neuroscientist, argues that sorting people into two broad buckets ignores substantial overlap and within-group variation. She notes that averages can miss individuals who don’t fit neatly into either category, with real consequences for diagnosis and treatment.

"Ignoring the overlaps between pink and blue buckets could have real consequences" - Donna Maney

Ambien and Sex-Based Dosing: A Case Study

The podcast discusses a controversial example: the FDA’s 2013 decision to adjust the starting dose of the sleep aid Zolpidem (Ambien) for women. The pharmacokinetic difference suggests women may metabolize the drug differently, leading to longer sleep effects and potential morning impairment. Sarah Richardson, director of the gendersci lab at Harvard, highlights the debate: differences exist, but overlap remains, so dosing becomes a careful balance between safety and appropriate treatment.

"Ambien stays longer in women's systems than in men's, which means that a woman might be more sleepy the morning after taking it" - Sarah Richardson

Symptoms, Bias, and Treatment Delays

The episode emphasizes that women often present with different heart attack symptoms and may experience delays in treatment. While chest pain is common to all, women may report fatigue, indigestion, or other atypical symptoms. Marina DiMarco notes that focusing too narrowly on biology can obscure how society shapes care, such as disparities in how quickly women are evaluated in emergency settings.

"Studies as recently as this year show that women who come to the hospital with chest pain get seen by a doctor later than men do for the same symptoms" - Marina

Precision Medicine and Society: A Forward-Lacing Vision

The conversation pivots to precision medicine—not a guarantee of perfect outcomes yet, but a better framework for tailoring care to individuals. Angela Zhang, an clinician, envisions a future where care accounts for genes, hormones, and social context, while acknowledging that we are not there yet.

"we dream of this world of precision medicine where everyone gets exactly the care that's right for them" - Angela Zhang

Policy Implications and Practical Takeaways

The episode closes with calls to broaden inclusion policies beyond NIH-funded work, noting that much research is privately funded. The takeaway is not to erase sex differences but to study them with specificity, and to consider social determinants in interpreting results and guiding practice. The guests emphasize ongoing work to harmonize biology with the realities of how care is delivered and experienced in diverse populations.

Quotes in Context

"Focusing on biology as an explanation for differences in outcomes across members of social groups naturalizes inequality" - Marina DiMarco